

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Pilon et al.

RECEIVED

Serial No.

09/898,616

OCT 18 2002

Filed

July 2, 2001

TECH CENTER 1600/2900

For

METHODS FOR THE PRODUCTION OF PURIFIED RECOMBINANT HUMAN UTEROGLOBIN FOR THE TREATMENT OF INFLAMMATORY AND FIBROTIC

CONDITIONS

Group Art Unit

1647

Examiner

Unassigned

919 Third Avenue

New York, New York 10022

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents,
United States Patent and Trademark Office Box Sequence
P.O. Box 2327
Arlington, VA 22202, on October 9, 2002

Barry Evans, Esq. Reg.No. 22,802

Name of Applicant, Assignee or Registered

Representative

Signatu

October 9, 2002

Date of Signature

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Formalities Letter, namely the Notice to Comply with

Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid

Sequence Disclosures, Applicants submit herewith (1) initial paper copy of a sequence listing, (2) a computer readable form (CFR) copy of the sequence listing; which applicants believe conforms to the requirements of 37 C.F.R. 1.824 and was run through Checker, the Patent and Trademark's freeware for checking Sequence submissions; and (3) a statement that the CRF copy is identical to the paper copy and that no new matter is introduced by entering the sequence listing into the application.

Applicants also submit herewith a Petition for Extension of Time for responding to the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed June 11, 2002 for two (2) months from August 11, 2002 up to and including October 11, 2002 and our Check No. 6433 in the amount of \$200.00 in payment of the petition fee for a small entity. In the event that any additional fees are due, please charge Deposit Account No. 50-0540.

Respectfully submitted,

KRAMER LEVIN NAFTALIS & FRANKEL LLP Attorneys for Applicants

By:

Barry Evans

Reg. No. 22,802 (212) 715-7609



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER FILING/RECEIPT DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NUMBER 09/898,616

07/02/2001 Aprile L. Pilon 116142/00170

KRAMER LEVIN NAFTALIS & FRANKEL LLP 919 THIRD AVENUE NEW YORK, NY 10022

CONFIRMATION NO. 3118 **FORMALITIES LETTER** OC000000008262273*

Date Mailed: 06/11/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

· A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

RECEIVED

OUT 18 2002

TECH CENTER 1600/2900

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE